title: Overexpression of CPS1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy.
abstract: Locally advanced rectal cancers are currently treated with neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery, but stratification of risk and final outcomes remain suboptimal. In view of the fact that glutamine metabolism is usually altered in cancer, we profiled and validated the significance of genes involved in this pathway in rectal cancers treated with CCRT. From a published transcriptome of rectal cancers (GSE35452), we focused on glutamine metabolic process-related genes (GO:0006541) and found upregulation of carbamoyl phosphate synthetase 1 (CPS1) gene most significantly predicted poor response to CCRT. We evaluated the expression levels of CPS1 using immunohistochemistry to analyze tumor specimens obtained during colonoscopy from 172 rectal cancer patients. Expression levels of CPS1 were further correlated with major clinicopathological features and survivals in this validation cohort. To further confirm CPS1 expression levels, Western blotting was performed for human colon epithelial primary cell (HCoEpiC) and four human colon cancer cells, including HT29, SW480, LoVo, and SW620. CPS1 overexpression was significantly related to advanced posttreatment tumor (T3, T4; P = 0.006) and nodal status (N1, N2; P < 0.001), and inferior tumor regression grade (P = 0.004). In survival analyses, CPS1 overexpression was significantly associated with shorter disease-specific survival (DSS) and metastasis-free survival (MeFS). Furthermore, using multivariate analysis, it was also independently predictive of worse DSS (P = 0.021, hazard ratio = 2.762) and MeFS (P = 0.004, hazard ratio = 3.897). CPS1 protein expression, as detected by Western blotting, is more abundant in colon cancer cells than nonneoplastic HCoEpiC. Overexpression of CPS1 is associated with poor therapeutic response and adverse outcomes among rectal cancer patients receiving CCRT, justifying the potential theranostic value of CPS1 for such patients.
authors.affiliation: Department of Pathology, Chi Mei Medical Center, Tainan, Taiwan.
authors.forename: Yi-Ying
authors.initials: YY
authors.lastname: Lee
authors.forename: Chien-Feng
authors.initials: CF
authors.lastname: Li
authors.forename: Ching-Yih
authors.initials: CY
authors.lastname: Lin
authors.forename: Sung-Wei
authors.initials: SW
authors.lastname: Lee
authors.forename: Ming-Jen
authors.initials: MJ
authors.lastname: Sheu
authors.forename: Li-Ching
authors.initials: LC
authors.lastname: Lin
authors.forename: Tzu-Ju
authors.initials: TJ
authors.lastname: Chen
authors.forename: Ting-Feng
authors.initials: TF
authors.lastname: Wu
authors.forename: Chung-Hsi
authors.initials: CH
authors.lastname: Hsing
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002222:Carbamoyl-Phosphate Synthase (Ammonia) / Q000378:metabolism*; D059248:Chemoradiotherapy; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011379:Prognosis; D012004:Rectal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D015996:Survival Rate
chemical_list: D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D002222:Carbamoyl-Phosphate Synthase (Ammonia); D005472:Fluorouracil
references.citation: Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):664-74
references.pmid: 12062610
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Tumour Biol. 2014 Jul;35(7):6823-30
references.pmid: 24729124
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Gastroenterology Res. 2009 Oct;2(5):277-281
references.pmid: 27956971
references.citation: Cancer. 2003 Jan 15;97(2):517-24
references.pmid: 12518377
references.citation: PLoS One. 2014 Apr 24;9(4):e96185
references.pmid: 24763545
references.citation: J Clin Oncol. 2004 Oct 1;22(19):3958-64
references.pmid: 15459218
references.citation: Nat Rev Cancer. 2011 Feb;11(2):85-95
references.pmid: 21258394
references.citation: J Clin Pathol. 2012 Aug;65(8):687-92
references.pmid: 22569540
references.citation: Cancer Biol Ther. 2011 Dec 15;12(12):1085-97
references.pmid: 22236876
references.citation: Hum Mutat. 2013 Aug;34(8):1149-59
references.pmid: 23649895
references.citation: J Clin Pathol. 2004 Jan;57(1):48-53
references.pmid: 14693835
references.citation: Am J Clin Pathol. 2004 Jun;121(6):884-92
references.pmid: 15198362
references.citation: N Engl J Med. 2004 Oct 21;351(17):1731-40
references.pmid: 15496622
references.citation: Cell Cycle. 2010 Oct 1;9(19):3884-6
references.pmid: 20948290
references.citation: Tumour Biol. 2014 Jan;35(1):161-9
references.pmid: 23897555
references.citation: Am J Clin Pathol. 2009 Jul;132(1):80-5
references.pmid: 19864237
references.citation: Eur J Intern Med. 2014 Jan;25(1):82-6
references.pmid: 24268837
references.citation: Ann Surg. 2005 May;241(5):829-36; discussion 836-8
references.pmid: 15849519
references.citation: Annu Rev Nutr. 1995;15:133-59
references.pmid: 8527215
references.citation: Am J Clin Pathol. 2004 Nov;122(5):721-7
references.pmid: 15491968
references.citation: Gene. 2012 Feb 10;493(2):228-34
references.pmid: 22173106
references.citation: Cell. 2009 May 1;137(3):560-70
references.pmid: 19410549
references.citation: Am J Pathol. 1993 Oct;143(4):1050-4
references.pmid: 7692729
references.citation: Clin Cancer Res. 2013 Jun 1;19(11):2861-72
references.pmid: 23549872
references.citation: Tumour Biol. 2014 Aug;35(8):7755-63
references.pmid: 24810927
references.citation: Mod Pathol. 2003 Feb;16(2):137-44
references.pmid: 12591966
references.citation: Am J Pathol. 2011 Feb;178(2):652-61
references.pmid: 21281797
references.citation: Tumour Biol. 2014 Jan;35(1):179-87
references.pmid: 23897556
references.citation: Lab Invest. 2008 Jan;88(1):78-88
references.pmid: 18026163
references.citation: Cell Death Dis. 2013 Mar 07;4:e532
references.pmid: 23470539
references.citation: Nat Rev Cancer. 2010 Apr;10(4):267-77
references.pmid: 20300106
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8688-96
references.pmid: 16246976
references.citation: Cytogenet Cell Genet. 1995;71(3):266-7
references.pmid: 7587391
references.citation: Mitochondrion. 2007 May;7(3):204-10
references.pmid: 17188582
references.citation: FASEB J. 2014 Jul;28(7):3225-37
references.pmid: 24687991
references.citation: Int J Colorectal Dis. 1997;12(1):19-23
references.pmid: 9112145
references.citation: Cancer Res. 2014 Feb 1;74(3):896-907
references.pmid: 24285724